Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Medical System HoldingsCHSYF +0.11%85 Debt-to-EBITDA is 0.36 as of Dec. 2025, which is 16% below its 10-year median of 0.43. GuruFocus rates CHSYF with a GF Score™ of 85/100 and a GF Value™ of $1.30 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 691 Drug Manufacturers companies, China Medical System Holdings ranks better than 76.7% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for China Medical System Holdings's Debt-to-EBITDA or its related term are showing as below:
CHSYF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.2 Med: 0.43 Max: 1.01
Current: 0.33
During the past 13 years, the highest Debt-to-EBITDA Ratio of China Medical System Holdings was 1.01. The lowest was 0.20. And the median was 0.43.
CHSYF's Debt-to-EBITDA is ranked better than 76.7% of 691
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs CHSYF: 0.33
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
China Medical System Holdings Debt-to-EBITDA Related Terms
China Medical System Holdings Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Medical System Holdings Debt-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Medical System Holdings Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where China Medical System Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
China Medical System Holdings (CHSYF) has a Debt-to-EBITDA of 0.36 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China Medical System Holdings. This is 16% below median its historical median of 0.43. Over the past decade, China Medical System Holdings' Debt-to-EBITDA has ranged from 0.20 to 1.01. According to the industry distribution chart, China Medical System Holdings ranks #161 out of 691 companies in the Drug Manufacturers industry, placing it in the top 23.3%.
Is China Medical System Holdings' Debt-to-EBITDA too high?
China Medical System Holdings' current Debt-to-EBITDA of 0.36 is 16% below median its 10-year median of 0.43. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 1.01. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. China Medical System Holdings' value of 0.36 is 78% below this industry median. Based on the distribution chart, China Medical System Holdings ranks #161 out of 691 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Medical System Holdings has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Medical System Holdings' Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Medical System Holdings ranks #161 out of 691 companies for Debt-to-EBITDA. This places China Medical System Holdings in the top 23% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.64. China Medical System Holdings' value of 0.36 is 78% below this benchmark. Historically, China Medical System Holdings' own Debt-to-EBITDA has ranged from 0.20 to 1.01 over the past decade. While the company's 10-year median is 0.43 vs. the industry median of 1.64, China Medical System Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Medical System Holdings's current Debt-to-EBITDA of 0.36 is 78% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China Medical System Holdings. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Medical System Holdings's current Debt-to-EBITDA is 0.36, which is 16% below median its own 10-year median of 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Medical System Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Medical System Holdings (CHSYF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.30, compared to a current price of $1.57 — trading 20.8% above its estimated fair value. The current Debt-to-EBITDA is 0.36, which is 16% below median its 10-year median of 0.43 and 78% below the Drug Manufacturers industry median of 1.64. China Medical System Holdings' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For China Medical System Holdings (CHSYF), the current Debt-to-EBITDA is 0.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Medical System Holdings (CHSYF) Overvalued in 2026?
Based on GuruFocus' analysis, China Medical System Holdings stock appears to be overvalued.
The current stock price of $1.57 is trading 20.8% above its estimated GF Value™ of $1.30.
GuruFocus considers China Medical System Holdings to be Modestly Overvalued.
Key valuation signals for CHSYF:
Debt-to-EBITDA: 0.36 (16% below median its 10-year median of 0.43)
GF Value™: $1.30 vs. price of $1.57 (20.8% above fair value)
Industry Position: 78% below the Drug Manufacturers median (#161 of 691)
No single metric tells the full story. See the CHSYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Medical System Holdings Ltd is a holding company. Along with its subsidiaries, it is engaged in the research and development, production, promotion and sale of medicines. The company's reportable segments are: (i) Integrated pharmaceuticals portfolio and (ii) Skin diseases related business. The majority of the company's revenue, which consists of pharmaceutical products sales, is derived from the integrated pharmaceuticals portfolio segment.
85GF Score
Get the complete analysis for CHSYF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHSYF has been successfully added to your 
